Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Transcription Factor Inhibition: Lessons Learned and Emerging Targets

Transcription Factor Inhibition: Lessons Learned and Emerging Targets

Thumbnail Image
Download
Name

Koehler, A. (2020).zip

Size

322.61 KB

Format

ZIP

Checksum (MD5)

b5df670ebd55b38b5b2d5d46c77f2e09

Thumbnail Image
Download
Name

Trends in Molecular Medicine review resubmission (final with CW edits).pdf

Size

365.21 KB

Format

Adobe PDF

Checksum (MD5)

067b6c609b1b0e75e62dd27b656bd057

Author(s)
Chen, Andrew
•
Koehler, Angela Nicole
Date Issued
February 2020
Journal
Trends in Molecular Medicine
Publisher
Elsevier BV
Citation
Chen, Andrew and Angela Nicole Koehler. "Transcription Factor Inhibition: Lessons Learned and Emerging Targets." Trends in Molecular Medicine 26, 5 (May 2020) © 2020 Elsevier Ltd
Version
Author's final manuscript
Abstract
Transcription factors have previously been nominated as targets in disease due to their location in focal points of signaling pathways. Significant progress has been made for many of these previously suggested transcription factors, including the STAT family, NF-κB, and Myc, resulting in small molecules inhibiting transcription factor activity in cell culture, and in some cases, in vivo. The cancer dependency map project uncovered many critical proteins in human cancers based on genome-wide loss-of-function screens, and transcription factors represent a large class of the dependencies. Among these, a number of transcription factors, including Myb, have limited or no suitable small molecule probes, and chemical probe research on these transcription factors will be a major area of interest moving forward.Transcription factors have roles at focal points in signaling pathways, controlling many normal cellular processes, such as cell growth and proliferation, metabolism, apoptosis, immune responses, and differentiation. Their activity is frequently deregulated in disease and targeting this class of proteins is a major focus of interest. However, the structural disorder and lack of binding pockets have made design of small molecules for transcription factors challenging. Here, we review some of the most recent developments for small molecule inhibitors of transcription factors emphasized in James Darnell’s vision 17 years ago. We also discuss the progress so far on transcription factors recently nominated by genome-scale loss-of-function screens from the cancer dependency map project.
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
http://creativecommons.org/licenses/by-nc-nd/4.0/
Persistent DSpace Link
https://hdl.handle.net/1721.1/125849
DOI of Published Version
https://doi.org/10.1016/j.molmed.2020.01.004
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.